References
- Northway WH, Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967;276(7):357–368. doi:https://doi.org/10.1056/NEJM196702162760701.
- Bancalari E, Claure N, Sosenko IR. Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. Semin Neonatol. 2003;8(1):63–71. doi:https://doi.org/10.1016/S1084-2756(02)00192-6.
- Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med. 2007;357(19):1946–1955. doi:https://doi.org/10.1056/NEJMra067279.
- Ali Z, Schmidt P, Dodd J, Jeppesen DL. Bronchopulmonary dysplasia: a review. Arch Gynecol Obstet. 2013;288(2):325–333. doi:https://doi.org/10.1007/s00404-013-2753-8.
- Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, Maniscalco WM. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1971–1980. doi:https://doi.org/10.1164/ajrccm.164.10.2101140.
- O’Reilly M, Thébaud B. Animal models of bronchopulmonary dysplasia. The term rat models. Am J Physiol Lung Cell Mol Physiol. 2014;307(12):L948–L958. doi:https://doi.org/10.1152/ajplung.00160.2014.
- Ladha F, Bonnet S, Eaton F, Hashimoto K, Korbutt G, Thébaud B. Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. Am J Respir Crit Care Med. 2005;172(6):750–756. doi:https://doi.org/10.1164/rccm.200503-510OC.
- Jakkula M, Le Cras TD, Gebb S, et al. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol. 2000;279(3):L600–L607. doi:https://doi.org/10.1152/ajplung.2000.279.3.L600.
- Le Cras TD, Markham NE, Tuder RM, Voelkel NF, Abman SH. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physiol Lung Cell Mol Physiol. 2002;283(3):L555–L562. doi:https://doi.org/10.1152/ajplung.00408.2001.
- Tang JR, Markham NE, Lin YJ, et al. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol. 2004;287(2):L344–L351. doi:https://doi.org/10.1152/ajplung.00291.2003.
- Tang JR, Seedorf G, Balasubramaniam V, Maxey A, Markham N, Abman SH. Early inhaled nitric oxide treatment decreases apoptosis of endothelial cells in neonatal rat lungs after vascular endothelial growth factor inhibition. Am J Physiol Lung Cell Mol Physiol. 2007;293(5):L1271–L1280. doi:https://doi.org/10.1152/ajplung.00224.2007.
- Park HS, Park JW, Kim HJ, et al. Sildenafil alleviates bronchopulmonary dysplasia in neonatal rats by activating the hypoxia-inducible factor signaling pathway. Am J Respir Cell Mol Biol. 2013;48(1):105–113. doi:https://doi.org/10.1165/rcmb.2012-0043OC.
- Abounahia FF, Abu Jarir R, Abounahia MF, et al. Prophylactic sildenafil in preterm infants at risk of bronchopulmonary dysplasia: a pilot randomized, double-blinded, placebo-controlled trial. Clin Drug Investig. 2019;39(11):1093–1107. doi:https://doi.org/10.1007/s40261-019-00834-0.
- van der Graaf M, Rojer LA, Helbing W, Reiss I, Etnel JRG, Bartelds B. EXPRESS: sildenafil for bronchopulmonary dysplasia and pulmonary hypertension: a meta-analysis. Pulm Circ. 2019;9:2045894019837875. doi:https://doi.org/10.1177/2045894019837875.
- Donda K, Zambrano R, Moon Y, et al. Riociguat prevents hyperoxia-induced lung injury and pulmonary hypertension in neonatal rats without effects on long bone growth. PLoS One. 2018;13(7):e0199927. doi:https://doi.org/10.1371/journal.pone.0199927.
- Nawa N, Ishida H, Katsuragi S, et al. Constitutively active form of natriuretic peptide receptor 2 ameliorates experimental pulmonary arterial hypertension. Mol Ther Methods Clin Dev. 2016;3:16044. doi:https://doi.org/10.1038/mtm.2016.44.
- Lang M, Kojonazarov B, Tian X, et al. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One. 2012;7(8):e43433. doi:https://doi.org/10.1371/journal.pone.0043433.
- Abman SH. Bronchopulmonary dysplasia: "a vascular hypothesis". Am J Respir Crit Care Med. 2001;164(10 Pt 1):1755–1756. doi:https://doi.org/10.1164/ajrccm.164.10.2109111c.
- Poggi C, Giusti B, Gozzini E, et al. Genetic contributions to the development of complications in preterm newborns. PLoS One. 2015;10(7):e0131741. doi:https://doi.org/10.1371/journal.pone.0131741.
- Kallapur SG, Bachurski CJ, Le Cras TD, Joshi SN, Ikegami M, Jobe AH. Vascular changes after intra-amniotic endotoxin in preterm lamb lungs. Am J Physiol Lung Cell Mol Physiol. 2004;287(6):L1178–L1185. doi:https://doi.org/10.1152/ajplung.00049.2004.
- Ballard RA, Truog WE, Cnaan A, et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med. 2006;355(4):343–353. doi:https://doi.org/10.1056/NEJMoa061088.
- Khemani E, McElhinney DB, Rhein L, et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics. 2007;120(6):1260–1269. doi:https://doi.org/10.1542/peds.2007-0971.
- Hilgendorff A, Apitz C, Bonnet D, Hansmann G. Pulmonary hypertension associated with acute or chronic lung diseases in the preterm and term neonate and infant. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart. 2016;102 Suppl 2(Suppl):ii49–ii56. doi:https://doi.org/10.1136/heartjnl-2015-308591.